TESARO Inc (NASDAQ:TSRO)‘s stock had its “market perform” rating reiterated by equities researchers at Leerink Swann in a research note issued to investors on Monday.
Several other research firms have also weighed in on TSRO. Morgan Stanley lifted their price objective on TESARO from $172.00 to $186.00 and gave the company an “overweight” rating in a research note on Wednesday, March 1st. Cowen and Company set a $155.00 price objective on TESARO and gave the company a “hold” rating in a research note on Saturday, February 25th. Robert W. Baird lowered TESARO from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $127.00 to $182.00 in a research note on Monday, February 27th. FBR & Co lowered TESARO from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $151.00 to $202.00 in a research note on Thursday, February 16th. Finally, SunTrust Banks, Inc. reaffirmed an “average” rating and issued a $190.00 price objective on shares of TESARO in a research note on Thursday, February 9th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $160.27.
TESARO (NASDAQ:TSRO) traded up 1.37% during midday trading on Monday, reaching $152.05. The company had a trading volume of 508,649 shares. The firm’s market capitalization is $8.15 billion. The firm’s 50-day moving average price is $173.60 and its 200 day moving average price is $135.82. TESARO has a 12 month low of $36.68 and a 12 month high of $192.94.
var userip;Your IP Address: document.write(userip);
In related news, SVP Martin H. Jr. Huber sold 190 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $136.26, for a total transaction of $25,889.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Edward C. English sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $178.06, for a total value of $1,780,600.00. Following the transaction, the vice president now directly owns 5,396 shares in the company, valued at $960,811.76. The disclosure for this sale can be found here. Insiders have sold a total of 15,793 shares of company stock worth $2,801,638 over the last three months. 40.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in TESARO during the fourth quarter valued at about $40,158,000. Putnam Investments LLC increased its stake in TESARO by 0.4% in the fourth quarter. Putnam Investments LLC now owns 10,429 shares of the biopharmaceutical company’s stock valued at $1,402,000 after buying an additional 46 shares in the last quarter. Senzar Asset Management LLC acquired a new stake in TESARO during the fourth quarter valued at about $19,136,000. Castleark Management LLC acquired a new stake in TESARO during the fourth quarter valued at about $10,845,000. Finally, Teachers Retirement System of The State of Kentucky increased its stake in TESARO by 124.6% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 33,992 shares of the biopharmaceutical company’s stock valued at $4,572,000 after buying an additional 18,857 shares in the last quarter. 98.48% of the stock is currently owned by hedge funds and other institutional investors.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.